| DIRECT COMPETITOR COMPARISON | |
| RIGL | AMGN | AIMM.OB | Pvt1 | Industry | | Market Cap: | 388.66M | 57.15B | 6.88M | N/A | 128.60M | | Employees: | 181 | 16,700 | N/A | N/A | 181 | | Qtrly Rev Growth (yoy): | N/A | -1.60% | 315.80% | N/A | 14.60% | | Revenue (ttm): | N/A | 14.58B | 616.00K | N/A | 31.21M | | Gross Margin (ttm): | N/A | 84.99% | 74.03% | N/A | 72.61% | | EBITDA (ttm): | -118.39M | 6.71B | N/A | N/A | -1.65M | | Oper Margins (ttm): | N/A | 38.71% | -60.88% | N/A | 2.37% | | Net Income (ttm): | -119.82M | 4.74B | -383.00K | N/A | N/A | | EPS (ttm): | -3.235 | 4.585 | -0.023 | N/A | N/A | | P/E (ttm): | N/A | 12.32 | N/A | N/A | 13.73 | | PEG (5 yr expected): | N/A | 1.31 | N/A | N/A | 2.18 | | P/S (ttm): | N/A | 3.92 | 11.18 | N/A | 3.28 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.465 | -0.06% | 57.15B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.055 | 0.29% | 13.61B | 15.75 | | Genzyme Corp. | GENZ | 50.80 | -0.53% | 13.48B | 28.96 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.25 | -0.67% | 41.62B | 17.88 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.45 | -1.00% | 8.82B | 1009.18 | | Teva Pharmaceutical Industries Limited | TEVA | 52.62 | -0.49% | 46.36B | 48.14 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.22 | 0.70% | 3.95B | 19.19 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.85 | -0.84% | 2.94B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.87 | -0.78% | 5.46B | 109.63 | | Pfizer Inc. | PFE | 18.25 | 0.00% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.59 | -0.48% | 172.69B | 13.67 | | GlaxoSmithKline plc | GSK | 41.30 | -2.27% | 104.70B | 13.11 | | Sanofi-Aventis | SNY | 37.85 | -1.51% | 98.83B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.46 | 0.14% | 125.96B | 16.60 | | RHHBY.PK | 40.85 | -1.47% | N/A | N/A | | AstraZeneca plc | AZN | 44.636 | -1.44% | 64.72B | 8.96 | | Abbott Laboratories | ABT | 54.18 | 0.18% | 83.80B | 14.68 | | Bristol-Myers Squibb Co. | BMY | 25.43 | 0.20% | 50.38B | 13.16 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AMGN | | Amgen Highlights Data to be Presented at ASH
Mon 8:51am -
PR Newswire | | • | AMGN | | The Comeback Kids: The Interviews
Mon 5:01am -
at SmartMoney.com | | • | AMGN | | Soft-talking revolutionary
Sun 5:50pm -
at FT.com | | • | AMGN | | 8 HealthCare Stocks With 3%+ Dividends
Sun 12:52am -
at Seeking Alpha | | • | AMGN | | Less Toxic Monoclonal Antibodies And Increased Patent Protection For Biologics Creates Multiple Positive Investment Scenarios In Biotechnology Sector
Sat, Nov 28 -
Wall Street Transcript | | • | AMGN | | This Big Winner Has Hit Its Prime
Fri, Nov 27 -
at Motley Fool | | • | AIMM.OB | | AUTOIMMUNE INC Financials
Thu, Nov 19 -
EDGAR Online Financials | | • | AIMM.OB | | AUTOIMMUNE INC Files SEC form 10-Q, Quarterly Report
Fri, Nov 13 -
EDGAR Online | | • | AIMM.OB | | AUTOIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Thu, Nov 12 -
EDGAR Online | | • | AIMM.OB | | AutoImmune Inc. Reports 2009 Third Quarter Financial Results
Tue, Nov 10 -
PR Newswire | | • | AIMM.OB | | AutoImmune Inc. Initiates Strategic Alternatives Process
Wed, Oct 21 -
PR Newswire | | | All Headlines for these symbols... |
|
|
|
0.12% Nasdaq 
Competitors
